GMP IPO Watch
Nippon India Nifty Pharma ETF
Direct Plan · Nippon India Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +2.98% | +3.62% | 166 of 229 |
| 1M | +3.86% | +2.76% | 90 of 227 |
| 3M | +2.76% | -3.72% | 2 of 227 |
| 6M | +16.69% | -0.45% | 1 of 218 |
| YTD | +21.22% | -3.05% | 2 of 229 |
| 1Y | +22.83% | -0.32% | 10 of 193 |
| 2Y | +10.36% | +4.05% | 18 of 150 |
| 3Y | +22.93% | +11.19% | 7 of 125 |
| 5Y | +15.06% | +8.24% | 5 of 73 |
| INCEPTION | +13.35% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Other ETF.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.57% | +26.99% | -13.77% | 63% | 25% |
| 6M | +7.45% | +34.46% | -15.89% | 65% | 26% |
| 1Y | +16.64% | +65.21% | -15.30% | 74% | 32% |
| 2Y | +19.42% | +38.51% | -1.84% | 98% | 45% |
| 3Y | +20.29% | +27.68% | +12.32% | 100% | 48% |
| 5Y | +13.57% | +15.07% | +12.37% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.94%
- Debt0.00%
- Cash0.06%
- Other0.00%
Market Cap Split
- Large Cap46.31%
- Mid Cap46.08%
- Small Cap7.55%
- Others0.06%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.33 | — |
| P/B | 5.12 | — |
| Price / Sales | 5.63 | — |
| Price / Cash Flow | 29.45 | — |
| Dividend Yield (%) | 0.68 | — |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 19.50% | -1.25% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 11.97% | +0.09% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 7.82% | +0.46% |
| Cipla | Pharmaceuticals & Biotechnology | 7.68% | -0.15% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 7.62% | +0.67% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 7.16% | -0.18% |
| Lupin | Pharmaceuticals & Biotechnology | 5.00% | -0.25% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.69% | +0.00% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.56% | -0.13% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 3.16% | +0.08% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.92% | +0.05% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.88% | +0.18% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.71% | +0.00% |
| Biocon | Pharmaceuticals & Biotechnology | 2.62% | -0.28% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.34% | +0.07% |
View all 23 holdings
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 2.14% | +0.15% |
| Wockhardt | Pharmaceuticals & Biotechnology | 1.77% | +0.23% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.67% | +0.17% |
| Abbott | Pharmaceuticals & Biotechnology | 1.43% | +0.10% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.30% | -0.02% |
| Triparty Repo | Reverse Repo / TREPS | 0.18% | — |
| Cash Margin - CCIL | Net Current Assets | 0.00% | — |
| Net Current Assets | Net Current Assets | -0.12% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 14.11 | 16.71 | Low Volatility |
| 3Y | 15.18 | 15.13 | High Volatility |
| 5Y | 15.05 | 14.14 | High Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.31 | -3.33 | Above Average |
| 3Y | 1.07 | -1.59 | Above Average |
| 5Y | 0.62 | -1.39 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.45 | 0.07 | Above Average |
| 3Y | 2.17 | 2.33 | Below Average |
| 5Y | 1.52 | 1.11 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.80 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.93 | 0.96 | Good Risk Adjusted Returns |
| 5Y | 0.94 | 0.94 | None |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Motilal Oswal Nasdaq Q50 ETF | +33.42% | +31.36% | — | +12.73% |
| Tata Silver Exchange Traded Fund | +26.44% | — | — | +39.36% |
|
SBI Silver ETF
Regular Plan · Growth
|
+26.42% | — | — | +34.10% |
| Kotak Silver ETF | +26.35% | +36.48% | — | +28.03% |
| ICICI PRUDENTIAL SILVER ETF | +26.35% | +36.57% | — | +24.10% |
| Edelweiss Silver ETF | +26.32% | — | — | +35.41% |
| Motilal Oswal Silver ETF | +26.09% | — | — | +46.27% |
|
Nippon India Silver ETF
Direct Plan
|
+26.05% | +36.23% | — | +25.08% |
|
HDFC Silver ETF
Growth Option
|
+25.77% | +36.06% | — | +34.08% |
| Motilal Oswal Nifty Capital Market ETF | +20.03% | — | — | +45.83% |
More From Nippon Life India Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Direct Plan · Growth Option
|
+61.78% | +49.40% | — | +24.96% |
|
Nippon India Silver ETF
Direct Plan
|
+26.05% | +36.23% | — | +25.08% |
|
Nippon India Silver ETF FOF
Direct Plan · IDCW Option
|
+24.99% | +35.38% | — | +24.09% |
|
Nippon India Japan Equity Fund
Direct Plan · IDCW Option
|
+20.27% | +21.27% | +9.63% | +9.56% |
|
Nippon India ETF Gold BeES
Direct Plan
|
+16.58% | +30.82% | +23.10% | +15.30% |
|
Nippon India Gold Savings Fund
Direct Plan · Growth Option
|
+16.51% | +30.76% | +22.97% | +10.34% |
|
Nippon India US Equity Opportunities Fund
Direct Plan · IDCW Option
|
+11.90% | +18.73% | +10.93% | +14.93% |
|
Nippon India Pharma Fund
Direct Plan · Growth Option
|
+10.54% | +18.85% | +14.53% | +17.34% |
|
Nippon India Fixed Maturity Plan - XLV - Series 5
Direct Plan · Growth Option
|
+7.36% | +8.43% | — | +8.54% |
|
Nippon India Credit Risk Fund (Existing Number of Segregated Portfolios - 1)
Regular Plan · Institutional Plan-Growth Option
|
+7.34% | +8.29% | +7.32% | +7.21% |
About This Scheme
Investment Objective
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Securities constituting securities constituting Nifty Pharma Index - 95% to 100%, Money Market Instruments including TriParty Repo on governement securities or T-Bills, cash & cash equivalents or Liquid Schemes - 0% to 5%.
Exit Load
Not Applicable
Fund Managers
Jitendra Tolani
Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.